Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Fernanda de Morais Marques, Verena Pfister, Flavia Parra, Mihoko Yamamoto, MD PhD, Rodrigo Santucci Silva, MD, Marcelo Bellesso, MD, Vinicius Campos de Molla, MD, Ana Rita Da Fonseca, MD, Yana Novis, MD, Sérgio Costa Fortier, MD, Talita Silveira, MD PhD, Guilherme Brasil Duffles Amarante, MD, Valeria Buccheri, Matheus Vescovi, MD PhD, Carlos Sérgio Chiattone, MD PhD, Celso Arrais, MD PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142810

Published: 2020

Journal Articles

Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients

Vinicius Campos Molla, MD, Roberta Azevedo, Jessica Fernandes Ramos, MD PhD, Danilo Belchior Ponciano, Pedro Henrique Arruda de Moraes, MD, Ana Rita Da Fonseca, MD, Maria Cristina Nunez Seiwald, MD, Mariana Serpa, MD, Aliana Meneses Ferreira, MD, Roberta Shcolnik Szor, MD, Rayana Bomfim Leonel, MD, Erick Menezes Xavier, MD, Vanderson Rocha, MD PhD, Luciana Tucunduva, MD, Yana Novis, MD, Marcio Nucci, MD PhD, Esper Kallas, MD PhD, Celso Arrais, MD PhD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-142111

Published: 2020

Journal Articles

Long-Term Follow-up of Ruxolitinib in Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (GVHD)

Aliana Meneses Ferreira, MD, Vinicius Campos Molla, MD, Maria Cristina Nunez Seiwald, MD, Roberta Shcolnik Szor, MD, Pedro Henrique Arruda De Moraes, MD, Ana Rita Da Fonseca, MD, Mariana Serpa, MD, Erick Menezes Xavier, MD, Luciana Tucunduva, MD, Yana Novis, MD, Celso Arrais-Rodrigues, MD PhD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-141452

Published: 2020

Journal Articles

"Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose"

Roberta Azevedo, Vinicius Campos Molla, MD, Jessica Fernandes Ramos, MD PhD, Danilo Belchior Ponciano, Pedro Henrique Arruda De Moraes, MD, Ana Rita Da Fonseca, MD, Maria Cristina Nunez Seiwald, MD, Mariana Serpa, MD, Aliana Meneses Ferreira, MD, Roberta Shcolnik Szor, MD, Rayana Bomfim Leonel, MD, Erick Menezes Xavier, MD, Luciana Tucunduva, MD, Vanderson Rocha, MD PhD, Yana Novis, MD, Esper Kallas, MD PhD, Marcio Nucci, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-142112

Published: 2020

Journal Articles

Ikaros Expression in the Graft Is Associated with Chronic Graft Versus Host Disease

Andre Domingues Pereira, MD, Vinicius Campos de Molla, MD, Ana Rita Da Fonseca, MD, Yana Novis, MD, Marcela Souza Pires, Ana Popi, PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-138981

Published: 2020

Journal Articles

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Nayara Ribeiro Guedes, MD, Ana Rita Da Fonseca, MD, Thiago Xavier Carneiro, MD PhD, Vinicius Campos de Molla, MD, Rodrigo Santucci Silva, MD, Sérgio Costa Fortier, MD, Vera Lucia de Piratininga Figueiredo, MD, Larissa Ommati, MD, Valeria Buccheri, MD PhD, Gislaine Borba Oliveira, MD, Leila Martins Perobelli, MD, Fernando Sergio Blumm Ferreira, MD, Matheus Vescovi, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 1764.

https://doi.org/10.1182/blood-2019-125626

Published: 2019

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Matheus Vescovi, MD PhD, Iara Baldim Rabelo Gomes, MD PhD, Ismael Dale Cotrim Guerreiro da Silva, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2229.

https://doi.org/10.1182/blood-2019-126241

Published: 2019

Journal Articles

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

Ana Rita Da Fonseca, MD, Anita Hill, MD PhD, Patricia Eiko Yamakawa, MD, Iara Baldim Rabelo, MD PhD, Andre Domingues Pereira, MD, Vinicius Campos de Molla, MD, Matheus Vescovi Gonçalves, MD PhD, Morag Griffin, MD, Talha Munir, MD, Peter Hillmen, MD PhD, Louise Arnold, MD, Kathryn Riley, MD, Antonio M. Risitano, MD PhD, Phillip Scheinberg, MD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2503.

https://doi.org/10.1182/blood-2019-130719

Published: 2019

Journal Articles

PIG-a Mutations in a Brazilian Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Caio Perez Gomes, Agatha Mendes, Fabiana Bettoni, PhD, Vinicius Campos de Molla, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Joao Bosco Pesquero, PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 944.

https://doi.org/10.1182/blood-2019-132033

Published: 2019

NARROW

Favorable Outcome in CLL Patients Not Treated Despite Presenting Iwcll Criteria: A Retrospective Analysis of the Brazilian CLL Group

Increased Risk of for Cytomegalovirus Reactivation after Allogeneic HSCT in T-Cell Depleted Patients

Long-Term Follow-up of Ruxolitinib in Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease (GVHD)

"Low Dose Ganciclovir for Cytomegalovirus Reactivation after Allogeneic HSCT Is a Feasible Option with Same Efficacy and Less Toxicity Than Regular Dose"

Ikaros Expression in the Graft Is Associated with Chronic Graft Versus Host Disease

Ibrutinib Maintenance after Chemoimmunotherapy Is Feasible and Results in Excellent Progression-Free and Overall Survival in Patients with Detectable MRD after Chemoimmunotherapy

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Subcutaneous Alemtuzumab Has Activity in Treatment-Naïve Patients with Acquired Aplastic Anemia

PIG-a Mutations in a Brazilian Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only